Welcome to our dedicated page for Shattuck Labs news (Ticker: STTK), a resource for investors and traders seeking the latest updates and insights on Shattuck Labs stock.
Shattuck Labs, Inc. (NASDAQ: STTK) is a clinical-stage biotechnology company at the forefront of developing innovative bi-functional fusion proteins. These unique proteins represent a new class of biologic medicine aimed at treating patients with cancer and autoimmune diseases. Shattuck's proprietary Agonist Redirected Checkpoint (ARC®) platform is designed to inhibit checkpoint molecules and activate costimulatory molecules with a single therapeutic, a groundbreaking approach in the biotechnology field.
The company's lead product candidate, SL-172154 (SIRPα-Fc-CD40L), is engineered to block the CD47 immune checkpoint and activate the CD40 pathway simultaneously. Currently, SL-172154 is in multiple Phase 1 clinical trials targeting various cancers, including platinum-resistant ovarian cancer and acute myeloid leukemia (AML). Another promising candidate, SL-279252 (PD1-Fc-OX40L), is being developed in collaboration with Takeda Pharmaceuticals and is also in Phase 1 trials.
Shattuck Labs recently embarked on an exciting collaboration with Ono Pharmaceutical to develop bifunctional fusion proteins for autoimmune and inflammatory diseases. This partnership includes a significant financial package with potential milestone payments and royalties, reinforcing Shattuck's strong financial condition and innovative capabilities. Additionally, the company's proprietary gamma delta T cell engager platform, GADLEN™, promises to bridge gamma delta T cells to tumor antigens, offering new hope for cancer treatment.
Recent achievements include rapid enrollment in clinical trials and the FDA's orphan drug designation for SL-172154, highlighting the urgent need for new AML treatments. Shattuck is also actively participating in several high-profile conferences, sharing their latest research and clinical progress. The company is headquartered in Austin, Texas, and Durham, North Carolina, and continues to leverage its scientific expertise to address unmet medical needs.
- Core Business: Development of bi-functional fusion proteins for cancer and autoimmune diseases.
- Recent Achievements: FDA orphan drug designation for SL-172154, collaboration with Ono Pharmaceutical.
- Current Projects: Phase 1 trials for SL-172154 and SL-279252, development of GADLEN™ platform.
- Financial Condition: Strong financial backing with potential milestone payments from partnerships.
- Partnerships: Collaborations with Ono Pharmaceutical and Takeda Pharmaceuticals.
Shattuck Labs (NASDAQ: STTK), a biotechnology company focused on developing therapeutics targeting TNF superfamily receptors for inflammatory and immune-related diseases, announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The event will take place in San Francisco from January 13-16, 2025.
Dr. Taylor Schreiber, CEO of Shattuck, will deliver a corporate update presentation on January 16, 2025, at 7:30 a.m. PT at The Westin St. Francis in the Elizabethan B room. The presentation will be available via live webcast on the company's website, with a replay accessible for up to 30 days afterward.
Shattuck Labs (NASDAQ: STTK) provided a corporate update highlighting key milestones for 2025, focusing on their DR3 blocking antibody program, SL-325. The company plans to present preclinical data at upcoming scientific conferences and expects several significant developments, including:
- GLP toxicology study data readout in Q1 2025
- IND filing in Q3 2025
- Phase 1 clinical trial initiation in Q3 2025
- DR3 bispecific development candidate nomination in H2 2025
The company reports a strong financial position with $90.1 million in cash, cash equivalents, and investments as of September 30, 2024, which is expected to fund operations into 2027. Management expressed optimism about SL-325's potential to achieve complete blockade of the DR3/TL1A signaling pathway based on non-human primate studies.
Shattuck Labs (NASDAQ: STTK), a biotechnology company developing novel therapeutics targeting TNF superfamily receptors for cancer and chronic immune-related diseases treatment, announced its participation in two upcoming investor conferences. The company's CEO, Dr. Taylor Schreiber, will present at the Piper Sandler 36th Annual Healthcare Conference on December 3, 2024, at 12:30 p.m. ET, and participate in a fireside chat at the Evercore 7th Annual HealthCONx Conference on December 4, 2024, at 8:45 a.m. ET. Live webcasts will be available on the company's website with replays archived for up to 90 days.
Shattuck Labs (NASDAQ: STTK) reported Q3 2024 financial results and announced a strategic shift to focus on SL-325, a first-in-class DR3 blocking antibody. The company ended Q3 with $90.1 million in cash and investments, compared to $101.1 million year-over-year. Q3 net loss was $16.7 million ($0.33 per share), improved from $27.5 million ($0.65 per share) in Q3 2023. R&D expenses decreased to $16.3 million from $24.2 million, while G&A expenses reduced to $4.6 million from $5.1 million. The company completed restructuring plans and expects current cash to fund operations into 2027, beyond SL-325's Phase 1 trial results.
Shattuck Labs (Nasdaq: STTK) announced a strategic pipeline prioritization, discontinuing its SL-172154 clinical program due to modest improvements in overall survival for TP53 mutant AML and HR-MDS patients. The company will focus on SL-325, a first-in-class DR3 antagonist antibody for inflammatory bowel disease (IBD), with an IND filing expected in Q3 2025.
Key points:
- SL-172154 showed only modest improvement in median overall survival compared to azacitidine monotherapy benchmarks
- Approximately 40% workforce reduction as part of restructuring
- Cash runway extended into 2027
- Mutual termination of collaboration agreement with Ono Pharmaceutical
- SL-325 demonstrates high affinity binding and superior efficacy over TL1A antibodies in preclinical studies
Shattuck Labs (Nasdaq: STTK) reported Q2 2024 financial results and business highlights. Key points include:
1. Updated positive interim data from Phase 1B trial of SL-172154 with Azacitidine in HR-MDS and TP53m AML patients.
2. Enrollment ongoing in randomized Phase 1B dose-expansion cohort for frontline HR-MDS.
3. FDA granted Orphan Drug Designation for SL-172154 in AML treatment.
4. Q2 2024 financials: $105.3M cash and investments, $19.2M R&D expenses, $5.3M G&A expenses, $21.5M net loss ($0.42 per share).
5. Cash runway expected into 2026, beyond Phase 1 trial results for SL-172154.
Shattuck Labs (NASDAQ: STTK), a clinical-stage biotech company developing bi-functional fusion proteins for cancer and autoimmune disease treatment, announced its participation in the upcoming BTIG Virtual Biotechnology Conference. The event is scheduled for August 5-6, 2024. Dr. Taylor Schreiber, Shattuck's CEO, will engage in a fireside chat with BTIG analyst Kaveri Pohlman on August 5 at 2:00 p.m. ET. The company will also be available for one-on-one meetings during the conference. A live webcast of the fireside chat will be accessible to conference participants.
Shattuck Labs (Nasdaq: STTK), a clinical-stage biotechnology company focusing on bifunctional fusion proteins for cancer and autoimmune diseases, announced its inclusion in the Russell 2000® and Russell 3000® Indexes, effective July 1, 2024. This addition reflects the company's progress in advancing its lead candidate, SL-172154, in high-risk myelodysplastic syndromes (HR-MDS) and TP53-mutated acute myeloid leukemia (TP53m AML). The annual Russell U.S. Indexes reconstitution includes the 4,000 largest U.S. stocks, ranking them by market capitalization. The Russell Indexes are widely used by investment managers and institutional investors for index funds and benchmarking active investment strategies.
Shattuck Labs has revealed updated positive interim data from the Phase 1B clinical trial of SL-172154 combined with Azacitidine (AZA) for treating frontline higher-risk myelodysplastic syndromes (HR-MDS) and TP53 mutant acute myeloid leukemia (AML).
The trial showed a 67% objective response rate (ORR) in HR-MDS patients, with a 58% complete remission rate, while frontline TP53m AML patients exhibited a 43% ORR and 33% complete remission with incomplete hematologic recovery.
SL-172154 demonstrated a manageable safety profile, with the most common adverse events being infusion-related reactions. The median overall survival for both patient groups has not yet been reached.
Shattuck is focusing on HR-MDS and TP53m AML due to competition and potential for accelerated approval pathways. The company will host a conference call on June 14, 2024, to discuss these findings further.
Shattuck Labs announced that its lead clinical candidate, SL-172154, has been granted Orphan Drug Designation (ODD) by the U.S. FDA for the treatment of Acute Myeloid Leukemia (AML). This designation is awarded to drugs that address rare diseases affecting fewer than 200,000 people in the U.S. and provides benefits such as market exclusivity for seven years, tax credits for clinical trials, and waived application fees. The company plans to present additional data from the Phase 1B dose expansion clinical trial of SL-172154 at the European Hematology Association 2024 Congress.
FAQ
What is the current stock price of Shattuck Labs (STTK)?
What is the market cap of Shattuck Labs (STTK)?
What is Shattuck Labs, Inc.'s core business?
What are the main product candidates of Shattuck Labs?
What is the ARC® platform?
Who are Shattuck Labs' key partners?
Where is Shattuck Labs headquartered?
What is SL-172154?
What recent achievements has Shattuck Labs made?
What is the GADLEN™ platform?
What financial condition is Shattuck Labs in?
What are some upcoming events for Shattuck Labs?
